Eli Lilly and Company (LLY) - Net Assets
Based on the latest financial reports, Eli Lilly and Company (LLY) has net assets worth $33.88 Billion USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($142.28 Billion) and total liabilities ($108.40 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Eli Lilly and Company (LLY) strategic investment index to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $33.88 Billion |
| % of Total Assets | 23.81% |
| Annual Growth Rate | 6.21% |
| 5-Year Change | 189.85% |
| 10-Year Change | 88.45% |
| Growth Volatility | 30.81 |
Eli Lilly and Company - Net Assets Trend (1985–2025)
This chart illustrates how Eli Lilly and Company's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see LLY company net worth.
Annual Net Assets for Eli Lilly and Company (1985–2025)
The table below shows the annual net assets of Eli Lilly and Company from 1985 to 2025. Also explore Eli Lilly and Company equity growth rate to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $26.54 Billion | +85.93% |
| 2024-12-31 | $14.27 Billion | +31.37% |
| 2023-12-31 | $10.86 Billion | +0.82% |
| 2022-12-31 | $10.78 Billion | +17.70% |
| 2021-12-31 | $9.15 Billion | +57.16% |
| 2020-12-31 | $5.83 Billion | +115.82% |
| 2019-12-31 | $2.70 Billion | -75.26% |
| 2018-12-31 | $10.91 Billion | -6.50% |
| 2017-12-31 | $11.67 Billion | -17.13% |
| 2016-12-31 | $14.08 Billion | -3.49% |
| 2015-12-31 | $14.59 Billion | -5.18% |
| 2014-12-31 | $15.39 Billion | -12.77% |
| 2013-12-31 | $17.64 Billion | +19.40% |
| 2012-12-31 | $14.77 Billion | +9.15% |
| 2011-12-31 | $13.54 Billion | +9.05% |
| 2010-12-31 | $12.41 Billion | +30.31% |
| 2009-12-31 | $9.53 Billion | +41.42% |
| 2008-12-31 | $6.74 Billion | -49.80% |
| 2007-12-31 | $13.42 Billion | +22.19% |
| 2006-12-31 | $10.98 Billion | +1.75% |
| 2005-12-31 | $10.79 Billion | -1.17% |
| 2004-12-31 | $10.92 Billion | +11.83% |
| 2003-12-31 | $9.76 Billion | +18.02% |
| 2002-12-31 | $8.27 Billion | +16.46% |
| 2001-12-31 | $7.10 Billion | +17.48% |
| 2000-12-31 | $6.05 Billion | +20.62% |
| 1999-12-31 | $5.01 Billion | +13.17% |
| 1998-12-31 | $4.43 Billion | -7.82% |
| 1997-12-31 | $4.81 Billion | -21.22% |
| 1996-12-31 | $6.10 Billion | +12.29% |
| 1995-12-31 | $5.43 Billion | +1.44% |
| 1994-12-31 | $5.36 Billion | +17.22% |
| 1993-12-31 | $4.57 Billion | -6.61% |
| 1992-12-31 | $4.89 Billion | -1.49% |
| 1991-12-31 | $4.97 Billion | +43.22% |
| 1990-12-31 | $3.47 Billion | -7.71% |
| 1989-12-31 | $3.76 Billion | +16.49% |
| 1988-12-31 | $3.23 Billion | +6.00% |
| 1987-12-31 | $3.04 Billion | +11.06% |
| 1986-12-31 | $2.74 Billion | +14.74% |
| 1985-12-31 | $2.39 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Eli Lilly and Company's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 792.9% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $24.47 Billion | 92.22% |
| Common Stock | $590.00 Million | 2.22% |
| Other Comprehensive Income | $-2.88 Billion | -10.85% |
| Other Components | $4.36 Billion | 16.41% |
| Total Equity | $26.54 Billion | 100.00% |
Eli Lilly and Company Competitors by Market Cap
The table below lists competitors of Eli Lilly and Company ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Walmart Inc
SA:WALM34
|
$1.03 Trillion |
|
Space Exploration Technologies Corp. Class A Common Stock
NASDAQ:SPCX
|
$1.19 Trillion |
|
SK Hynix Inc. American Depositary Shares
NASDAQ:SKHY
|
$1.30 Trillion |
|
Tesla Inc
NASDAQ:TSLA
|
$1.31 Trillion |
|
Samsung Electronics Co Ltd
KO:005930
|
$1.01 Trillion |
|
JPMorgan Chase & Co
NYSE:JPM
|
$928.53 Billion |
|
Walmart Inc. Common Stock
NYSE:WMT
|
$898.72 Billion |
|
Eli Lilly and Company
SA:LILY34
|
$853.51 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Eli Lilly and Company's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 14,192,100,000 to 26,535,000,000, a change of 12,342,900,000 (87.0%).
- Net income of 20,638,300,000 contributed positively to equity growth.
- Dividend payments of 5,384,000,000 reduced retained earnings.
- Share repurchases of 4,108,000,000 reduced equity.
- Other comprehensive income increased equity by 1,441,900,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $20.64 Billion | +77.78% |
| Dividends Paid | $5.38 Billion | -20.29% |
| Share Repurchases | $4.11 Billion | -15.48% |
| Other Comprehensive Income | $1.44 Billion | +5.43% |
| Other Changes | $-245.30 Million | -0.92% |
| Total Change | $- | 86.97% |
Book Value vs Market Value Analysis
This analysis compares Eli Lilly and Company's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 39.00x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 531.54x to 39.00x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1985-12-31 | $2.17 | $1152.44 | x |
| 1986-12-31 | $2.50 | $1152.44 | x |
| 1987-12-31 | $2.65 | $1152.44 | x |
| 1988-12-31 | $2.84 | $1152.44 | x |
| 1989-12-31 | $3.20 | $1152.44 | x |
| 1990-12-31 | $3.01 | $1152.44 | x |
| 1991-12-31 | $4.27 | $1152.44 | x |
| 1992-12-31 | $4.21 | $1152.44 | x |
| 1993-12-31 | $3.81 | $1152.44 | x |
| 1994-12-31 | $4.59 | $1152.44 | x |
| 1995-12-31 | $4.62 | $1152.44 | x |
| 1996-12-31 | $5.46 | $1152.44 | x |
| 1997-12-31 | $4.11 | $1152.44 | x |
| 1998-12-31 | $3.95 | $1152.44 | x |
| 1999-12-31 | $4.53 | $1152.44 | x |
| 2000-12-31 | $5.52 | $1152.44 | x |
| 2001-12-31 | $6.52 | $1152.44 | x |
| 2002-12-31 | $7.64 | $1152.44 | x |
| 2003-12-31 | $9.04 | $1152.44 | x |
| 2004-12-31 | $10.01 | $1152.44 | x |
| 2005-12-31 | $9.87 | $1152.44 | x |
| 2006-12-31 | $10.10 | $1152.44 | x |
| 2007-12-31 | $12.38 | $1152.44 | x |
| 2008-12-31 | $6.15 | $1152.44 | x |
| 2009-12-31 | $8.67 | $1152.44 | x |
| 2010-12-31 | $11.23 | $1152.44 | x |
| 2011-12-31 | $12.16 | $1152.44 | x |
| 2012-12-31 | $12.88 | $1152.44 | x |
| 2013-12-31 | $15.79 | $1152.44 | x |
| 2014-12-31 | $13.84 | $1152.44 | x |
| 2015-12-31 | $13.18 | $1152.44 | x |
| 2016-12-31 | $12.72 | $1152.44 | x |
| 2017-12-31 | $11.02 | $1152.44 | x |
| 2018-12-31 | $10.55 | $1152.44 | x |
| 2019-12-31 | $2.72 | $1152.44 | x |
| 2020-12-31 | $5.90 | $1152.44 | x |
| 2021-12-31 | $9.42 | $1152.44 | x |
| 2022-12-31 | $11.21 | $1152.44 | x |
| 2023-12-31 | $11.93 | $1152.44 | x |
| 2024-12-31 | $15.70 | $1152.44 | x |
| 2025-12-31 | $29.55 | $1152.44 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Eli Lilly and Company utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 77.78%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 31.66%
- • Asset Turnover: 0.58x
- • Equity Multiplier: 4.24x
- Recent ROE (77.78%) is above the historical average (38.59%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1985 | 21.68% | 15.83% | 0.83x | 1.66x | $278.83 Million |
| 1986 | 20.38% | 15.00% | 0.81x | 1.68x | $284.24 Million |
| 1987 | 21.16% | 17.67% | 0.69x | 1.73x | $339.44 Million |
| 1988 | 23.59% | 18.70% | 0.77x | 1.63x | $438.47 Million |
| 1989 | 25.01% | 22.50% | 0.71x | 1.56x | $563.79 Million |
| 1990 | 32.51% | 21.71% | 0.73x | 2.06x | $780.55 Million |
| 1991 | 26.47% | 22.96% | 0.69x | 1.67x | $818.09 Million |
| 1992 | 14.49% | 11.49% | 0.71x | 1.77x | $219.49 Million |
| 1993 | 10.51% | 7.44% | 0.67x | 2.11x | $23.32 Million |
| 1994 | 24.01% | 22.52% | 0.39x | 2.71x | $750.54 Million |
| 1995 | 42.17% | 33.87% | 0.47x | 2.65x | $1.75 Billion |
| 1996 | 24.98% | 21.77% | 0.49x | 2.35x | $913.49 Million |
| 1997 | -8.29% | -4.82% | 0.64x | 2.71x | $-849.66 Million |
| 1998 | 47.36% | 22.71% | 0.73x | 2.84x | $1.65 Billion |
| 1999 | 54.28% | 27.20% | 0.78x | 2.56x | $2.22 Billion |
| 2000 | 50.57% | 28.15% | 0.74x | 2.43x | $2.45 Billion |
| 2001 | 39.13% | 24.08% | 0.70x | 2.31x | $2.07 Billion |
| 2002 | 32.73% | 24.45% | 0.58x | 2.30x | $1.88 Billion |
| 2003 | 26.22% | 20.35% | 0.58x | 2.22x | $1.58 Billion |
| 2004 | 16.58% | 13.06% | 0.56x | 2.28x | $718.11 Million |
| 2005 | 18.34% | 13.52% | 0.60x | 2.28x | $900.41 Million |
| 2006 | 24.25% | 16.97% | 0.71x | 2.00x | $1.56 Billion |
| 2007 | 21.87% | 15.85% | 0.70x | 1.98x | $1.60 Billion |
| 2008 | -30.76% | -10.17% | 0.70x | 4.34x | $-2.75 Billion |
| 2009 | 45.45% | 19.82% | 0.80x | 2.88x | $3.38 Billion |
| 2010 | 40.82% | 21.97% | 0.74x | 2.50x | $3.83 Billion |
| 2011 | 32.11% | 17.90% | 0.72x | 2.49x | $2.99 Billion |
| 2012 | 27.69% | 18.09% | 0.66x | 2.33x | $2.61 Billion |
| 2013 | 26.57% | 20.27% | 0.66x | 2.00x | $2.92 Billion |
| 2014 | 15.55% | 12.19% | 0.54x | 2.36x | $853.18 Million |
| 2015 | 16.53% | 12.07% | 0.56x | 2.44x | $951.27 Million |
| 2016 | 19.54% | 12.90% | 0.55x | 2.77x | $1.34 Billion |
| 2017 | -1.76% | -1.02% | 0.44x | 3.88x | $-1.36 Billion |
| 2018 | 29.63% | 15.04% | 0.49x | 4.02x | $2.14 Billion |
| 2019 | 319.09% | 37.27% | 0.57x | 15.07x | $8.06 Billion |
| 2020 | 109.79% | 25.24% | 0.53x | 8.27x | $5.63 Billion |
| 2021 | 62.16% | 19.71% | 0.58x | 5.44x | $4.68 Billion |
| 2022 | 58.64% | 21.88% | 0.58x | 4.65x | $5.18 Billion |
| 2023 | 48.65% | 15.36% | 0.53x | 5.94x | $4.16 Billion |
| 2024 | 74.62% | 23.51% | 0.57x | 5.55x | $9.17 Billion |
| 2025 | 77.78% | 31.66% | 0.58x | 4.24x | $17.98 Billion |
Industry Comparison
This section compares Eli Lilly and Company's net assets metrics with peer companies in the Drug Manufacturers - General industry.
Industry Context
- Industry: Drug Manufacturers - General
- Average net assets among peers: $11,286,554,702
- Average return on equity (ROE) among peers: 34.35%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Eli Lilly and Company (LLY) | $33.88 Billion | 21.68% | 3.20x | $1.03 Trillion |
| AbbVie Inc (ABBV) | $5.10 Billion | 104.16% | 12.89x | $356.49 Billion |
| Amgen Inc (AMGN) | $17.87 Billion | 17.72% | 0.94x | $198.99 Billion |
| Amarin Corporation PLC (AMRN) | $-5.96 Million | 0.00% | 0.00x | $290.84 Million |
| AstraZeneca PLC (AZN) | $2.32 Billion | 27.43% | 2.19x | $282.04 Billion |
| AstraZeneca PLC (AZN) | $682.84 Million | 62.71% | 7.94x | $248.20 Billion |
| Biogen Inc (BIIB) | $8.62 Billion | 21.60% | 0.38x | $31.14 Billion |
| Bristol-Myers Squibb Company (BMY) | $9.79 Billion | 31.74% | 1.80x | $128.36 Billion |
| Gilead Sciences Inc (GILD) | $21.53 Billion | 25.33% | 1.96x | $182.68 Billion |
| GlaxoSmithKline PLC ADR (GSK) | $3.64 Billion | 28.39% | 0.56x | $111.15 Billion |
| Johnson & Johnson (JNJ) | $43.32 Billion | 24.41% | 0.87x | $574.95 Billion |
About Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 7… Read more